极少量阳光暴露对骨骼健康的影响:红细胞生成性原卟啉症队列研究的启示
该单中心纵向双向队列研究纳入2012至2023年至少接受一次双能X线吸收测定(DXA)扫描的139例成人红细胞生成性原卟啉症(EPP)患者,基线时82.7%患者Z评分低于0 SD,骨量减少占39.5%、骨质疏松占15.3%,34.2%患者发生骨质疏松相关骨折。年龄增长、持续维生素D缺乏和低体重指数增加低骨密度几率;基线维生素D缺乏者及基线未使用胆钙化醇者改善骨密度的几率最高,阿法美拉诺肽未改善骨密度。
要点
- EPP患者基线低骨密度普遍,82.7%患者Z评分低于0 SD。
- 骨量减少占39.5%,骨质疏松占15.3%,34.2%患者发生骨质疏松相关骨折。
- 基线维生素D缺乏者改善骨密度几率最高(OR 5.51;95% CI,1.69-17.92)。
核心结论
- 25-羟基维生素D(25(OH)D)状态在预防低骨密度和改善骨密度中均起关键作用。
- EPP是缺乏阳光暴露和维生素D缺乏的自然模型,突显终身维持充足维生素D状态对普通人群骨骼健康的重要性。
研究设计与样本
- 单中心纵向双向队列研究,使用2012至2023年间至少接受一次双能X线吸收测定(DXA)扫描的成人EPP患者病历资料和两次问卷数据,共139例患者。
主要发现
- 基线时139例患者中82.7%的Z评分低于0 SD。
- 低骨密度分类为骨量减少者占39.5%,骨质疏松者占15.3%。
- 34.2%的患者发生50例骨质疏松相关骨折。
- 年龄增长(OR 1.08;CI,1.03-1.12)、持续维生素D缺乏(OR 1.11;95% CI,1.00-1.23)和低体重指数(OR 0.91;95% CI,0.82-0.99)增加低骨密度的几率。
- 基线维生素D缺乏者(OR 5.51;95% CI,1.69-17.92)和基线未使用胆钙化醇者(OR 0.22;95% CI,0.04-1.34)改善骨密度的几率最高;阿法美拉诺肽未改善骨密度。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Erythropoietic protoporphyria (EPP) is a rare inherited metabolic disease, causing lifelong painful phototoxic reactions, minimal sunlight exposure, and vitamin D deficiency. Previous studies reported a high osteoporosis prevalence in EPP patients. OBJECTIVE: To identify those at risk for low bone mineral density (BMD) and assess which factors, including treatment with cholecalciferol and afamelanotide, improve BMD in EPP. METHODS: A longitudinal ambispective single-center cohort study. Data from patient files and two-time questionnaires from adult patients with EPP who underwent at least one dual-energy x-ray absorptiometry (DXA) scan between 2012 and 2023 were used. RESULTS: BMD is low in EPP patients, with 82.7% of the 139 patients having a Z-score below 0 SD at baseline. Low BMD classified as osteopenia was found in 39.5%, and osteoporosis in 15.3%. There were 50 osteoporosis-related fractures in 34.2% of patients. Aging (odds ratio [OR] 1.08; CI, 1.03-1.12), persistent vitamin D deficiency (OR 1.11; 95% CI, 1.00-1.23) and a low body mass index (OR 0.91; 95% CI, 0.82-0.99) increased the odds of low BMD. Patients with a vitamin D deficiency (OR 5.51; 95% CI, 1.69-17.92) and no cholecalciferol at baseline (OR 0.22; 95% CI, 0.04-1.34) had the highest odds of improving their BMD. Afamelanotide did not improve BMD. CONCLUSION: 25-hydroxyvitamin D (25(OH)D) status plays a crucial role in both preventing low BMD and improving BMD. EPP is a natural model for lack of sunlight exposure and vitamin D deficiency, underlining the importance of lifelong adequate vitamin D status for bone health in the general population.
引用
- Kluijver LG, Wagenmakers MAEM, Wilson JHP, et al. The Impact of Minimal Sunlight Exposure on Bone Health: Insights From a Cohort Study in Erythropoietic Protoporphyria. J Clin Endocrinol Metab. 2025. PMID: 39401412. doi:10.1210/clinem/dgae729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。